Alphabiome, a Tel Aviv, Israel-based company advancing technology that extracts genetic biomarkers from microbial DNA, raised $8M in Seed funding.
The round was led by AIX Ventures alongside other investors.
The company intends to use the funds to expand operations and its R&D efforts.
Led by CEO and Founder Dr. Yaniv Altshuler, Alphabiome uses a proprietary AI model to decode the human microbiome, analyzing trillions of genetic fragments to identify high potential biomarkers.
Combining advanced AI and microbiome analytics, Alphabiome’s data-driven approach leverages sophisticated novel mathematical models and algorithms to identify previously uncharacterized microbial DNA patterns that are scattered across different chromosomes, microbes, and biological kingdoms. Valuable biomarkers are then extracted to predict drug efficacy with accuracy, unlocking new possibilities for precision medicine.
The company recently conducted a trial where microbiome samples were collected from a large number of Ulcerative Colitis and Crohn’s patients who were being treated with six different drugs. Its proprietary algorithm analyzed trillions of genetic data points and identified over 10,000 complex microbe-derived biomarkers related to the successful use of these drugs.
FinSMEs
06/05/2025